Myeloid Programs

Myeloid cells, such as immunosuppressive macrophages, play a significant role in shaping the immunosuppressive tumor microenvironment and are critical for tumor development. Consequently, blocking myeloid cells may offer a complementary strategy to checkpoint inhibitors and provide new treatment solutions for non-responsive or relapsing patients as well as expand the patient population responsive to immunotherapies.

Compugen’s discovery platform has identified multiple potential myeloid targets and the company is pursuing the research and development of novel therapeutics to further grow its pipeline.